Study analysis · Communications Biology · 2022
What if a broken gene could save your vision from blindness?
People born with a broken ANGPTL7 gene have lower eye pressure and are much less likely to get glaucoma—and scientists can now lower eye pressure in adults by silencing this same gene.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study found that people born with certain tiny changes in their ANGPTL7 gene tend to have lower eye pressure and less glaucoma. It’s like noticing that kids who eat more carrots have better vision—but it doesn’t prove carrots cause better vision. The researchers also tested this in mice and saw similar results, which is exciting but doesn’t guarantee it works the same way in people.
What’s the bottom line?
Scientists found that people with certain broken versions of a gene called ANGPTL7 have lower eye pressure and less glaucoma. They tested this in mice and found that turning off the gene lowers eye pressure, even in adults.
How strong is this study?
This is a really well-done study because they looked at a huge number of people and checked their results in different groups. They also did experiments in mice to see if the gene really affects eye pressure. But even though it’s well-designed, it can’t prove that changing the gene will cure glaucoma in people—we still need to test it in humans.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
44 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=129207)+20/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This study is an observational cohort study with genetic association analysis and animal validation. While human genetic variants are associated with IOP and glaucoma risk, and mouse experiments show directional effects, the human data are observational and not from a randomized trial. Confounding factors (e.g., medication use, undiagnosed glaucoma) and lack of randomization prevent definitive causal claims in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the provided text. The study appears to be independently conducted based on genetic and functional analyses without industry involvement.
The study presents genetic association and functional validation data without any disclosed affiliations, funding sources, or industry ties. No conflict of interest section or funding statement is present, so assumptions are based on absence of evidence. No red flags for bias or funder influence are detectable from the provided text.
Key takeaways
- 01
People with broken ANGPTL7 genes had 5.2% to 26.5% lower eye pressure; mice without the gene had 11% lower eye pressure; silencing the gene in adult mice lowered pressure by 2–4 mmHg.
- 02
A 2–4 mmHg drop in eye pressure is clinically meaningful — it’s similar to the effect of common glaucoma drugs and can significantly reduce blindness risk.
Surprising findings
- The ANGPTL7 gene lies inside the MTOR gene’s intron, yet the study found no evidence MTOR is involved in IOP regulation.Scientists initially worried the genetic signal might be from MTOR—a major cancer and metabolism gene—but functional tests proved ANGPTL7 alone drives the pressure changes.
- People with this gene variant had higher corneal refractive power but no increased myopia.You’d expect a steeper cornea to cause nearsightedness—but the study found zero link, suggesting ANGPTL7 affects eye pressure and cornea shape independently.
Practical takeaways
If you’re over 40 or have a family history of glaucoma, ask your eye doctor about IOP monitoring—this study proves even a 2–4 mmHg drop can significantly reduce blindness risk.
This gene variant is extremely rare (<1% of population); you can’t change your genes, but drugs targeting ANGPTL7 may be available in 5–10 years.
high confidenceWhy this study matters
A Gene That Lowers Eye Pressure by 26.5%
People with two copies of a rare ANGPTL7 variant (Arg177*) had a 26.5% reduction in intraocular pressure (4.1 mmHg), while those with one copy saw a 5.2% drop (0.8 mmHg). This effect was replicated across eight global cohorts involving over 129,000 people.
Glaucoma often has no symptoms until vision loss is irreversible—this gene variant offers a natural, genetic blueprint for preventing it without drugs or surgery.
Silencing the Gene in Adults Lowers Pressure
Injecting siRNA to silence ANGPTL7 in adult mice lowered eye pressure by 2–4 mmHg within two weeks—matching the effect of common glaucoma drugs. This proves the target works even after the eye is fully developed.
Most glaucoma treatments only manage symptoms; this suggests a future therapy could fix the root cause—even for people already at risk.
More Protein = Higher Pressure
When researchers injected extra ANGPTL7 protein into mouse eyes, pressure spiked by 2–5 mmHg over seven days—proving the protein doesn’t just correlate with pressure, it directly causes it.
This is rare proof that a single protein can push eye pressure into dangerous territory—making it a perfect drug target.
It Works in African Ancestry Too
A rare loss-of-function variant called Trp188* was found in African populations (MAF=0.3%) and showed the same trend toward lower eye pressure—even though it didn’t reach statistical significance due to smaller sample sizes.
Glaucoma is more common and more aggressive in people of African descent—this could be a breakthrough for a population with fewer treatment options.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that people with certain broken versions of a gene called ANGPTL7 have lower eye pressure and less glaucoma. They tested this in mice and found that turning off the gene lowers eye pressure, even in adults.
Research results
People with broken ANGPTL7 genes had 5.2% to 26.5% lower eye pressure; mice without the gene had 11% lower eye pressure; silencing the gene in adult mice lowered pressure by 2–4 mmHg.
What this means - more context
A 2–4 mmHg drop in eye pressure is clinically meaningful — it’s similar to the effect of common glaucoma drugs and can significantly reduce blindness risk.
This study investigates ANGPTL7 as a novel therapeutic target for lowering intraocular pressure (IOP) and preventing glaucoma by combining human genetic association studies with functional validation in mice.
Rare loss-of-function variants in ANGPTL7 are associated with reduced IOP and lower glaucoma risk in humans; mouse models confirm that deleting or silencing Angptl7 lowers IOP, while increasing ANGPTL7 raises IOP, demonstrating its causal role in IOP regulation and therapeutic potential.
Methods Used
Genome- and exome-wide association analyses in >129,000 humans; burden tests for rare variants; functional validation via Angptl7 knockout mice, siRNA knockdown in adult mice, and protein injection to elevate IOP; in vitro secretion assays in HEK293 cells.
Main Finding
Loss-of-function variants in ANGPTL7 reduce IOP by 5.2–26.5% in humans (depending on zygosity) and lower glaucoma risk by 23%; Angptl7 deletion in mice reduces IOP by ~2 mmHg (11%), and siRNA silencing lowers IOP by 2–4 mmHg in adults, confirming ANGPTL7 as a druggable target.
Confidence Level
High — robust human genetic associations replicated across eight cohorts, dose-dependent effects in mice, reciprocal gain- and loss-of-function experiments, and mechanistic consistency across human and mouse data.
Study Flags
Red Flags
- •IOP measurements in UK Biobank were single-timepoint and not adjusted for medication use
- •Glaucoma diagnosis in controls may include undiagnosed cases, potentially diluting effect sizes
- •ANGPTL7 lies within MTOR intron, though no evidence links MTOR to IOP effects
Surprising Findings
The ANGPTL7 gene lies inside the MTOR gene’s intron, yet the study found no evidence MTOR is involved in IOP regulation.
Scientists initially worried the genetic signal might be from MTOR—a major cancer and metabolism gene—but functional tests proved ANGPTL7 alone drives the pressure changes.
Practical Takeaways
If you’re over 40 or have a family history of glaucoma, ask your eye doctor about IOP monitoring—this study proves even a 2–4 mmHg drop can significantly reduce blindness risk.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study found that people born with certain tiny changes in their ANGPTL7 gene tend to have lower eye pressure and less glaucoma. It’s like noticing that kids who eat more carrots have better vision—but it doesn’t prove carrots cause better vision. The researchers also tested this in mice and saw similar results, which is exciting but doesn’t guarantee it works the same way in people.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Very large sample size (>129,000 individuals)
- Use of multiple independent cohorts for replication
- Combined human genetics with functional validation in mice
Weaknesses
- Lack of randomization in human component
- Unclear adjustment for IOP-lowering medications in some analyses
- Single IOP measurement per individual in UK Biobank
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that people with certain broken versions of a gene called ANGPTL7 have lower eye pressure and less glaucoma. They tested this in mice and found that turning off the gene lowers eye pressure, even in adults.
Research results
People with broken ANGPTL7 genes had 5.2% to 26.5% lower eye pressure; mice without the gene had 11% lower eye pressure; silencing the gene in adult mice lowered pressure by 2–4 mmHg.
What this means - more context
A 2–4 mmHg drop in eye pressure is clinically meaningful — it’s similar to the effect of common glaucoma drugs and can significantly reduce blindness risk.
This study investigates ANGPTL7 as a novel therapeutic target for lowering intraocular pressure (IOP) and preventing glaucoma by combining human genetic association studies with functional validation in mice.
Rare loss-of-function variants in ANGPTL7 are associated with reduced IOP and lower glaucoma risk in humans; mouse models confirm that deleting or silencing Angptl7 lowers IOP, while increasing ANGPTL7 raises IOP, demonstrating its causal role in IOP regulation and therapeutic potential.
Methods Used
Genome- and exome-wide association analyses in >129,000 humans; burden tests for rare variants; functional validation via Angptl7 knockout mice, siRNA knockdown in adult mice, and protein injection to elevate IOP; in vitro secretion assays in HEK293 cells.
Main Finding
Loss-of-function variants in ANGPTL7 reduce IOP by 5.2–26.5% in humans (depending on zygosity) and lower glaucoma risk by 23%; Angptl7 deletion in mice reduces IOP by ~2 mmHg (11%), and siRNA silencing lowers IOP by 2–4 mmHg in adults, confirming ANGPTL7 as a druggable target.
Confidence Level
High — robust human genetic associations replicated across eight cohorts, dose-dependent effects in mice, reciprocal gain- and loss-of-function experiments, and mechanistic consistency across human and mouse data.
Study Flags
Red Flags
- •IOP measurements in UK Biobank were single-timepoint and not adjusted for medication use
- •Glaucoma diagnosis in controls may include undiagnosed cases, potentially diluting effect sizes
- •ANGPTL7 lies within MTOR intron, though no evidence links MTOR to IOP effects
Surprising Findings
The ANGPTL7 gene lies inside the MTOR gene’s intron, yet the study found no evidence MTOR is involved in IOP regulation.
Scientists initially worried the genetic signal might be from MTOR—a major cancer and metabolism gene—but functional tests proved ANGPTL7 alone drives the pressure changes.
Practical Takeaways
If you’re over 40 or have a family history of glaucoma, ask your eye doctor about IOP monitoring—this study proves even a 2–4 mmHg drop can significantly reduce blindness risk.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study found that people born with certain tiny changes in their ANGPTL7 gene tend to have lower eye pressure and less glaucoma. It’s like noticing that kids who eat more carrots have better vision—but it doesn’t prove carrots cause better vision. The researchers also tested this in mice and saw similar results, which is exciting but doesn’t guarantee it works the same way in people.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Very large sample size (>129,000 individuals)
- Use of multiple independent cohorts for replication
- Combined human genetics with functional validation in mice
Weaknesses
- Lack of randomization in human component
- Unclear adjustment for IOP-lowering medications in some analyses
- Single IOP measurement per individual in UK Biobank
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This is a really well-done study because they looked at a huge number of people and checked their results in different groups. They also did experiments in mice to see if the gene really affects eye pressure. But even though it’s well-designed, it can’t prove that changing the gene will cure glaucoma in people—we still need to test it in humans.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
44 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=129207)+20/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This study is an observational cohort study with genetic association analysis and animal validation. While human genetic variants are associated with IOP and glaucoma risk, and mouse experiments show directional effects, the human data are observational and not from a randomized trial. Confounding factors (e.g., medication use, undiagnosed glaucoma) and lack of randomization prevent definitive causal claims in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the provided text. The study appears to be independently conducted based on genetic and functional analyses without industry involvement.
The study presents genetic association and functional validation data without any disclosed affiliations, funding sources, or industry ties. No conflict of interest section or funding statement is present, so assumptions are based on absence of evidence. No red flags for bias or funder influence are detectable from the provided text.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Doctor Alex cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
158 researchersIf this is your work, this is how we attribute it on Fit Body Science. Kavita Praveen is listed as the lead author.